Table 1 Clinical characteristics and administration of chemotherapy in 253 patients with primary resection for colorectal liver metastases
Variable, statistics | Estimate |
|---|---|
Age in years, median (range) | 66.1 (22.8, 89.2) |
Gender male/female ratio | 133/120 |
Synchronous metastasesa, n (%) | 115 (45.5) |
Disease-free intervalb in months, median (range) | 4 (-14,131) |
Resections, n | 253 |
   Hemihepatectomy/lobectomy, n (%) | 117 (46.2) |
   Wedge/segment resections, n (%) | 136 (53.8) |
   Simultaneous radiofrequency ablation, n (%) | 12 (4.7) |
   Two-stage resections, n (%) | 3 (1.2) |
   Simultaneous colorectal cancer surgery, n (%) | 14 (5.5) |
Extent of resection margin in mm, median (range) | 4 (0-50) |
Number of metastases, median (range) | 2 (1, 12) |
Metastases diameter in cm, median (range) | 3.0 (0.2,15.0) |
Bilobar metastases, n (%) | 94 (37.2) |
Number of resections/patient (1/2/3/4/5) | 203/36/11/2/1 |
In-hospital mortality, n (%) | 4 (1.6) |
Follow-up survivors in years, median (range) | 4.7 (1.9-12.9) |
Chemotherapy preoperatively, n (%) | 88 (34.8) |
   Downstaging, n (%) | 40 (15.8) |
   Perioperativec, n (%) | 43 (17.0) |
   Adjuvant after colon surgery, n (%) | 5 (2.0) |
Type of chemotherapy | Â |
   FOLFOXd, n (%) | 71 (81.6) |
   FOLFIRIe/+bevacizumab, n (%) | 8/3 (9.1/3.4) |
   FOLFIRI + cetuximab, n (%) | 1 (1.1) |
   FLVf, n (%) | 3 (3.4) |
   Other combinations, n (%) | 5 (5.7) |
Outcome of chemotherapyg (RECIST) | Â |
   Partial response, n (%) | 52 (59.1) |
   Stable disease, n (%) | 32 (36.4) |
   Progression, n (%) | 2 (2.3) |
   Unknown, n (%) | 2 (2.3) |
Number of cycles | Â |
   ≤3 | 11 (12.5) |
   4-6 | 40 (45.4) |
   7-12 | 27 (30.7) |
   >12 | 7 (8.0) |
   Unknown | 3 (3.4) |
Chemotherapy adjuvant, n (%) | 44 (17.4) |
   After neoadjuvant, n (%) | 30 (11.9) |
   After downstaging, n (%) | 7 (2.8) |
   Without preoperative chemotherapy, n (%) | 7 (2.8) |